In the present study, we investigated the effects and potential downstream pathway of Nlrp3 inflammasome activation in Ang II-induced cardiomyopathy, and whether targeting the Nlrp3 inflammasome could be a novel therapeutic approach for the treatment of Ang II-induced cardiac diseases. The gene discussed is NLRP3; the disease is cardiomyopathy.